Exelexis slashes workforce by 70%


US biotech firm Exelexis is cutting around 160 jobs (70% of its workforce). The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer (mCRPC).

The job cuts will leave behind just 70 employees, but the firm anticipates that the cost savings will leave it with ‘sufficient cash to support its operations through to the release of top-line results of [a trial of Cometriq in metastatic renal cell carcinoma] next year’.

A glance at Exelexis’ financial results reveals why such drastic cuts are needed. Cometriq is already approved in the US to treat metastatic medullary thyroid cancer, and brought in $6.5 million (£4 million) in revenue in the second quarter of 2014. However, the firm has made overall operating losses of over $55 million in each quarter of the last year, including spending $47–51 million on R&D. With only $87 million in working capital on its balance sheet, cutting staff and any peripheral clinical trial programmes allows the company to continue its most promising trials in the hope of positive results.


Related Content

Monsanto plans 2600 layoffs

12 October 2015 Business

news image

Sales losses prompt agrochemical giant to slash workforce by 12% over the next two years

Takeda slashes 10% of its workforce

20 January 2012 News Archive

news image

Japanese pharmaceutical firm sheds 2800 jobs in the US and Europe after recent takeover of Nycomed

Most Commented

Crawling chemical system acts as if it’s alive

24 May 2016 Research

news image

Intriguing globule that moves, eats and defecates

Let's see that again

27 May 2016 In the Pipeline

news image

Has chemistry evaded the reproducibility crises affecting other branches of science? Or is it just a question of scale, asks ...